DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



The Effect of Informative Letters on the Prescription and Receipt of Seroquel

Information source: Abdul Latif Jameel Poverty Action Lab
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Economics; Fraud; Delivery of Health Care; Health Expenditures; Centers for Medicare and Medicaid Services (U.S.)

Intervention: Placebo letter (Other); Initial Informative letter (Other); Followup Informative Letter (Other)

Phase: N/A

Status: Active, not recruiting

Sponsored by: Abdul Latif Jameel Poverty Action Lab

Official(s) and/or principal investigator(s):
Adam Sacarny, PhD, Principal Investigator, Affiliation: Harvard University and Robert Wood Johnson Foundation

Summary

Abusive prescribing exposes patients to unnecessary health risks and results in wasteful public expenditures. This study will evaluate an innovative approach to fighting abusive prescription: sending letters to suspected inappropriate prescribers warning them that they are outliers compared to their peers and have been flagged for review. The study will target high prescribers of Seroquel (Quetiapine), an atypical antipsychotic. Using claims data, the investigators will assess the effect of the letters on prescribing of Seroquel, receipt of Seroquel by patients, substitution behavior by prescribers and patients, and health outcomes of patients.

Clinical Details

Official title: The Effect of Informative Letters on the Prescription and Receipt of Seroquel

Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research

Primary outcome: 30-day equivalent prescribing of Seroquel treatments

Secondary outcome:

30-day equivalent prescribing of Seroquel treatments

30-day equivalent prescribing of Seroquel treatments

30-day equivalent prescribing of Seroquel treatments

30-day equivalent prescribing of Seroquel treatments

30-day equivalent prescribing of Seroquel treatments

Eligibility

Minimum age: N/A. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- General care practitioner

- Outlier with respect to the count of Seroquel prescription drug treatments relative

to peer group of prescribers in 2013 and 2014

- Outlier with respect to the count of Seroquel 30-day equivalent prescription drug

treatments relative to peer group of prescribers in 2013 and 2014 Exclusion Criteria:

- Deceased

Locations and Contacts

Additional Information

American Economic Association Randomized Controlled Trials Registry Entry

Starting date: April 2015
Last updated: June 10, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017